Table of Content




1. Executive Summary


2. Global Glioblastoma Multiforme Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges 


3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Glioblastoma Multiforme Market Trends (2018-2023) and Forecast (2024-2030)

3.3: Global Glioblastoma Multiforme Market by Treatment
3.3.1: Surgery
3.3.2: Radiation Therapy
3.3.3: Chemotherapy
3.3.4: Targeted Therapy
3.3.5: Tumor Treating Field Therapy
3.3.6: Immunotherapy

3.4: Global Glioblastoma Multiforme Market by Drug
3.4.1: Temozolomide
3.4.2: Bevacizumab
3.4.3: Lomustine
3.4.4: Carmustine Wafers
3.4.5: Others

3.5: Global Glioblastoma Multiforme Market by End Use
3.5.1: Hospitals
3.5.2: Clinics
3.5.3: Ambulatory Surgical Centers




4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Glioblastoma Multiforme Market by Region
4.2: North American Glioblastoma Multiforme Market
4.2.2: North American Glioblastoma Multiforme Market by End Use: Hospitals, Clinics, and Ambulatory Surgical Centers


4.3: European Glioblastoma Multiforme Market
4.3.1: European Glioblastoma Multiforme Market by Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field Therapy, and Immunotherapy
4.3.2: European Glioblastoma Multiforme Market by End Use: Hospitals, Clinics, and Ambulatory Surgical Centers


4.4: APAC Glioblastoma Multiforme Market
4.4.1: APAC Glioblastoma Multiforme Market by Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field Therapy, and Immunotherapy
4.4.2: APAC Glioblastoma Multiforme Market by End Use: Hospitals, Clinics, and Ambulatory Surgical Centers


4.5: ROW Glioblastoma Multiforme Market
4.5.1: ROW Glioblastoma Multiforme Market by Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field Therapy, and Immunotherapy
4.5.2: ROW Glioblastoma Multiforme Market by End Use: Hospitals, Clinics, and Ambulatory Surgical Centers



5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis


6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Glioblastoma Multiforme Market by Treatment
6.1.2: Growth Opportunities for the Global Glioblastoma Multiforme Market by Drug
6.1.3: Growth Opportunities for the Global Glioblastoma Multiforme Market by End Use
6.1.4: Growth Opportunities for the Global Glioblastoma Multiforme Market by Region

6.2: Emerging Trends in the Global Glioblastoma Multiforme Market

6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Glioblastoma Multiforme Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Glioblastoma Multiforme Market
6.3.4: Certification and Licensing


7. Company Profiles of Leading Players
7.1: Merck & Co
7.2: Amgen
7.3: F. Hoffmann-La Roche
7.4: Pfizer
7.5: Teva Pharmaceutical Industries
7.6: Sun Pharmaceutical Industries
7.7: Pharmaceuticals
7.8: Amneal Pharmaceuticals
7.9: Karyopharm Therapeutics
7.10: Sumitomo Dainippon Pharma Oncology